Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients who do not respond to current rheumatoid arthritis (RA) treatments may benefit from a new form of treatment that has been shown in a study to be effective against symptoms of the disease.

Image courtesy of Shutterstock

The RA-BEAM study is the first to demonstrate that the drug baricitinib is more effective in improving the symptoms of rheumatoid arthritis than the current standard treatment of injectable biologic anti-TNF medications. Baricitinib has been specifically developed as a treatment for rheumatoid arthritis.

Read more

Similar stories

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

General Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.